Roberto Marino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Roberto Marino has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
F Spadari
Unit of Oral Pathology and Medicine, University Dental Hospital, University of Milan
1 shared publicationFrancesco Spadari
Unit of Oral Pathology and Medicine, Department of Surgical, Reconstructive and Diagnostic Sciences, University of Milan, IRCCS Foundation Cà Granda‐Ospedale Maggiore Policlinico, Milan, Italy
1 shared publicationL Pignataro
Department of Otorhinolaryngological and Ophthalmological Sciences, Policlinico Foundation IRCCS, University of Milan, Milan, Italy
1 shared publicationLorenzo Pignataro
Department of Specialistic Surgical Sciences, University of Milan, Policlinico, Mangiagalli, Regina Elena, IRCCS Foundation, Milan, Italy
1 shared publicationP Capaccio
Department of Otorhinolaryngological and Ophthalmological Sciences, Policlinico Foundation IRCCS, University of Milan, Milan, Italy
1 shared publicationPasquale Capaccio
Department of Specialistic Surgical Sciences, University of Milan, Policlinico, Mangiagalli, Regina Elena, IRCCS Foundation, Milan, Italy
1 shared publication
Latest Publications
- 3 August 2010
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 39 (8) , 611-616
Different therapeutic strategies for burning mouth syndrome: preliminary data
To compare different therapeutic supportive approaches in patients with burning mouth syndrome. A prospective study was carried out for this purpose. The study involved 56 patients with burning mouth syndrome. They were randomly assigned to treatment with capsaicin, alpha-lipoic acid or lysozyme-lactoperoxidase (test drugs) or boric acid (control group). Symptoms were scored after 60 days treatment and 60 days after drug discontinuation. At the end of the treatment period, there was a significant reduction in the symptom scores of all of the patients who received the test drugs (P<0.01), and at the end of the follow-up period in the test groups as a whole (P<0.01); the reduction was not significant when considering each test group separately after the treatment period. All of the treatments were more effective than boric acid and there was no significant difference in the symptom scores of the control group at either of the study time-points. Our results demonstrate the similar effectiveness of capsaicin and alpha-lipoic acid in controlling the symptoms of burning mouth syndrome. Lysozyme-lactoperoxidase may be effective in the supportive care of BMS patients with xerostomia. The transitory effect observed after discontinuing drug administration justifies the use of prolonged therapy in chronically affected patients.
- 3 August 2010
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 39 (8) , 611-616
Different therapeutic strategies for burning mouth syndrome: preliminary data
To compare different therapeutic supportive approaches in patients with burning mouth syndrome. A prospective study was carried out for this purpose. The study involved 56 patients with burning mouth syndrome. They were randomly assigned to treatment with capsaicin, alpha-lipoic acid or lysozyme-lactoperoxidase (test drugs) or boric acid (control group). Symptoms were scored after 60 days treatment and 60 days after drug discontinuation. At the end of the treatment period, there was a significant reduction in the symptom scores of all of the patients who received the test drugs (P<0.01), and at the end of the follow-up period in the test groups as a whole (P<0.01); the reduction was not significant when considering each test group separately after the treatment period. All of the treatments were more effective than boric acid and there was no significant difference in the symptom scores of the control group at either of the study time-points. Our results demonstrate the similar effectiveness of capsaicin and alpha-lipoic acid in controlling the symptoms of burning mouth syndrome. Lysozyme-lactoperoxidase may be effective in the supportive care of BMS patients with xerostomia. The transitory effect observed after discontinuing drug administration justifies the use of prolonged therapy in chronically affected patients.
- 8 April 2009
- Published by Wiley in Oral Diseases
- Vol. 15 (4) , 255-258
Burning mouth syndrome: the role of contact hypersensitivity
Background: Burning mouth syndrome is a burning sensation or stinging disorder affecting the oral mucosa in the absence of any clinical signs or mucosal lesions. Some studies have suggested that burning mouth syndrome could be caused by the metals used in dental prostheses, as well as by acrylate monomers, additives and flavouring agents, although others have not found any aetiologic role for hypersensitivity to dental materials.Objective: To evaluate the extent and severity of adverse reactions to dental materials in a group of patients with burning mouth syndrome, and investigate the possible role of contact allergy in its pathogenesis.Materials and methods: We prospectively studied 124 consecutive patients with burning mouth syndrome (108 males; mean age 57 years, range 41–83), all of whom underwent allergen patch testing between 2004 and 2007.Results: Sixteen patients (13%) showed positive patch test reactions and were classified as having burning mouth syndrome type 3 or secondary burning mouth syndrome (Lamey’s and Scala’s classifications).Conclusion: Although we did not find any significant association between the patients and positive patch test reactions, it would be advisable to include hypersensitivity to dental components when evaluating patients experiencing intermittent oral burning without any clinical signs.
- 8 April 2009
- Published by Wiley in Oral Diseases
- Vol. 15 (4) , 255-258
Burning mouth syndrome: the role of contact hypersensitivity
Background: Burning mouth syndrome is a burning sensation or stinging disorder affecting the oral mucosa in the absence of any clinical signs or mucosal lesions. Some studies have suggested that burning mouth syndrome could be caused by the metals used in dental prostheses, as well as by acrylate monomers, additives and flavouring agents, although others have not found any aetiologic role for hypersensitivity to dental materials.Objective: To evaluate the extent and severity of adverse reactions to dental materials in a group of patients with burning mouth syndrome, and investigate the possible role of contact allergy in its pathogenesis.Materials and methods: We prospectively studied 124 consecutive patients with burning mouth syndrome (108 males; mean age 57 years, range 41–83), all of whom underwent allergen patch testing between 2004 and 2007.Results: Sixteen patients (13%) showed positive patch test reactions and were classified as having burning mouth syndrome type 3 or secondary burning mouth syndrome (Lamey’s and Scala’s classifications).Conclusion: Although we did not find any significant association between the patients and positive patch test reactions, it would be advisable to include hypersensitivity to dental components when evaluating patients experiencing intermittent oral burning without any clinical signs.